MMS Holdings, a data-focused contract research organization (CRO) in Canton Township, announced that Kevin Chartier has been named principal advisor of biostatistics and submissions planning.
In this role, Chartier will work with the biostatistics team across MMS global operations to support sponsors with complex studies and submissions. He has more than 25 years of experience, holding positions at Astellas Pharma, Novartis, Wyeth, Pfizer, and United BioSource Corp.
“At MMS, we pride ourselves on being able to provide our sponsors with the right experts to meet their goals,” says Michelle Gayari, executive vice president of global operational excellence and innovation at MMS. “With the addition of Dr. Chartier and his extensive experience in biostatistics and submissions planning to our global team, we continue to build on our best-in-class clinical trial design and data solutions for Sponsors and patients.”
Other responsibilities will include acting as the senior technical reviewer for complex biostatistics studies and advising sponsors on biostatistics methods and efficiencies for health authority submissions.
He will also contribute to MMS’ emerging biometrics service areas, data science using real world evidence and built-for-purpose technology, Datacise, adaptive trial design, and decentralized clinical trials (DCTs).
“I am excited to join an organization with a proven track record,” says Chartier. “Being able to get closer to the science and the data, and consulting with other drug developers.
“I plan on building upon this success and strive to provide MMS sponsors with innovative fit-for-purpose quantitative development strategies and study options to ensure optimal decision making. I’m looking forward to providing educational opportunities for MMS colleagues and sponsors who desire these services as well.”